Merck & Co.
Search results
Apr 2, 2024 · Roivant Sciences is a holding company that develops transformative medicines and technologies by building agile, focused companies called Vants. Learn about Roivant's model, pipeline, news, and careers.
- About Us
Roivant builds nimble subsidiaries or “Vants” to develop and...
- Pipeline
Our pipeline includes innovative product candidates across...
- Our Companies
New York. 151 W 42nd Street 15th Floor New York, NY 10036...
- For Investors
Roivant develops transformative medicines faster by building...
- Join Us
At Roivant, we employ the brightest minds from various...
- Stock Information
Today's High Today's Low 52 Week High 52 Week Low. Stock...
- Events & Presentations
Roivant 4Q and Fiscal Year 2022 Earnings Call Presentation...
- Press Releases
Roivant to Report Financial Results for the Fourth Quarter...
- About Us
Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy .
Roivant develops and commercializes medicines and technologies by creating focused companies called Vants. Learn about their pipeline, launch, culture, and vision.
Roivant is a biopharmaceutical company with a broad and differentiated pipeline of product candidates across immunology, oncology, hematology, and dermatology. It has run 10 positive Phase 3 trials since 2019 and has a nimble, entrepreneurial model of Vants.
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology...
Roivant is a biopharmaceutical company that develops and launches Vants, or nimble and focused biotech companies. Find stock information, press releases, and business updates on its investor relations website.
Roivant Sciences, a biopharmaceutical company with a mission to improve healthcare delivery, announced the close of its business combination with Montes Archimedes Acquisition Corp. and a concurrent PIPE financing. The company also held a virtual R&D Day to showcase its pipeline and discovery platform.
